Analysts Have Conflicting Sentiments on These Healthcare Companies: Zimmer Biomet Holdings (ZBH) and OrganiGram Holdings (OGI)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zimmer Biomet Holdings (ZBH – Research Report) and OrganiGram Holdings (OGI – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zimmer Biomet Holdings (ZBH)
Needham analyst Michael Matson maintained a Hold rating on Zimmer Biomet Holdings today. The company’s shares closed last Tuesday at $92.65.
According to TipRanks.com, Matson is a 2-star analyst with an average return of
Currently, the analyst consensus on Zimmer Biomet Holdings is a Hold with an average price target of $101.21, implying a 7.5% upside from current levels. In a report issued on February 2, Morgan Stanley also maintained a Hold rating on the stock with a $100.00 price target.
See the top stocks recommended by analysts >>
OrganiGram Holdings (OGI)
Alliance Global Partners analyst Aaron Grey maintained a Buy rating on OrganiGram Holdings today and set a price target of C$4.00. The company’s shares closed last Tuesday at $1.47.
According to TipRanks.com, Grey ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
OrganiGram Holdings has an analyst consensus of Strong Buy, with a price target consensus of $2.50, which is a 57.2% upside from current levels. In a report issued on January 27, Canaccord Genuity also initiated coverage with a Buy rating on the stock with a C$3.00 price target.
